InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

InMed Pharmaceuticals' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $28656.0 for Q4 2023.

• On a quarterly basis, Current Deferred Revenue rose 77.21% year-over-year to $28656.0 in Q4 2023; TTM through Dec 2023 was $28656.0, a 77.21% increase from a year earlier, with the FY2023 full-year figure at $16171.0, changed N/A from the prior year.
• Current Deferred Revenue improved to $28656.0 in Q4 2023 per INM's latest filing, from $16171.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $28656.0 in Q4 2023 and bottomed at $8390.0 in Q4 2021.
• The 3-year median for Current Deferred Revenue is $16171.0 (2022), against an average of $15737.3.
• Across the five-year window, Current Deferred Revenue soared 92.74% in 2022 and soared 77.21% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $8390.0 in 2021, then surged by 92.74% to $16171.0 in 2022, then surged by 77.21% to $28656.0 in 2023.
• Per Business Quant, the three latest INM Current Deferred Revenue figures stand at $28656.0 (Q4 2023), $16171.0 (Q2 2023), and $16171.0 (Q1 2023).